Fridays vs MEDVi (2026): prices, structure, verdict

On tirzepatide, Fridays is cheaper: $359 versus $399 a month all-in — a $40 monthly gap, $480 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Fridays is cheaper: $175 versus $299 a month all-in — a $124 monthly gap, $1,488 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Fridays: the record, condensed

Start with the load-bearing figure: $359 a month, all-in, is what Fridays charges for tirzepatide at the 10 mg basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Fridays is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #13 of 17 verified programs, with the floor $144/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $90 a month. A year at this figure: $4,308 monthly-billed.

Start with the load-bearing figure: $175 a month, all-in, is what Fridays charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $175 is the whole subscription, which makes Fridays unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #7 of 20 in the verified semaglutide index — $42/month above the floor (Oak Longevity, $133) — and sits $174 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,100.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

MEDVi: the record, condensed

On tirzepatide, the number that matters at MEDVi is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

Start with the load-bearing figure: $299 a month, all-in, is what MEDVi charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Fridays at $359, MEDVi at $399 — a $40 monthly spread that compounds to $480 over a maintenance year and $960 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $40 gap is exactly what it appears to be.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $175 (Fridays) against $299 (MEDVi). $124 a month sounds survivable; $1,488 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $124 gap is exactly what it appears to be.

A way to feel the $40 monthly gap: over a year it funds 1.3 extra months at Fridays’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $960, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Fridays $359/mo month-to-month against MEDVi $399/mo month-to-month. The order holds: Fridays leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Fridays $1,077 monthly; MEDVi $1,197 monthly — best path favors Fridays by $120. 6 months: Fridays $2,154 monthly; MEDVi $2,394 monthly — best path favors Fridays by $240. 12 months: Fridays $4,308 monthly; MEDVi $4,788 monthly — best path favors Fridays by $480. 24 months: Fridays $8,616 monthly; MEDVi $9,576 monthly — best path favors Fridays by $960.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Fridays $525 vs MEDVi $897 — $372 to Fridays. 6 mo: Fridays $1,050 vs MEDVi $1,794 — $744 to Fridays. 12 mo: Fridays $2,100 vs MEDVi $3,588 — $1,488 to Fridays. 24 mo: Fridays $4,200 vs MEDVi $7,176 — $2,976 to Fridays.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Fridays publishes “not published”; MEDVi publishes “priced differently in CA/NC on some plans” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Fridays — annual plan for lowest rate; not published. MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

Evidence: Fridays third-party reported (captured 2026-08-05); MEDVi source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #13 and #14 of 17: between them lie 0 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #7 and #18 of 20: between them lie 10 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Fridays and MEDVi

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fridays: not published; MEDVi: 12-month plan applies to lowest rate) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings